BioCentury | Oct 9, 2006
Company News

Lorus board of directors update

...Inc. (TSX:LOR; LRP), Toronto, Ontario Business: Cancer, Gene/Cell therapy Appointed: Georg Ludwig, managing director of ConPharm...
BioCentury | Jan 31, 2000
Company News

Conpharm, Meda sales and marketing update

...CONP's Reumacon, a mixture of two benzylidenated podophyllotoxin glucosides that is under review in Sweden. Conpharm AB...
BioCentury | Sep 8, 1998
Clinical News

Conpharm regulatory update

...of its Reumacon rheumatoid arthritis compound, which is a mixture of two benzylidenated podophyllotoxin glucosides. Conpharm AB...
Items per page:
1 - 3 of 3
BioCentury | Oct 9, 2006
Company News

Lorus board of directors update

...Inc. (TSX:LOR; LRP), Toronto, Ontario Business: Cancer, Gene/Cell therapy Appointed: Georg Ludwig, managing director of ConPharm...
BioCentury | Jan 31, 2000
Company News

Conpharm, Meda sales and marketing update

...CONP's Reumacon, a mixture of two benzylidenated podophyllotoxin glucosides that is under review in Sweden. Conpharm AB...
BioCentury | Sep 8, 1998
Clinical News

Conpharm regulatory update

...of its Reumacon rheumatoid arthritis compound, which is a mixture of two benzylidenated podophyllotoxin glucosides. Conpharm AB...
Items per page:
1 - 3 of 3